Gilead Sciences, Inc. $GILD Stake Raised by Trek Financial LLC

Trek Financial LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 282.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 62,949 shares of the biopharmaceutical company’s stock after acquiring an additional 46,509 shares during the period. Trek Financial LLC’s holdings in Gilead Sciences were worth $9,383,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Walled Lake Planning & Wealth Management LLC boosted its position in shares of Gilead Sciences by 1.1% during the third quarter. Walled Lake Planning & Wealth Management LLC now owns 54,879 shares of the biopharmaceutical company’s stock worth $8,180,000 after buying an additional 603 shares during the period. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Gilead Sciences by 22.3% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,038,316 shares of the biopharmaceutical company’s stock valued at $155,188,000 after buying an additional 189,152 shares in the last quarter. Virtue Capital Management LLC raised its holdings in shares of Gilead Sciences by 12.8% in the 3rd quarter. Virtue Capital Management LLC now owns 3,151 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 357 shares during the period. Greenleaf Trust raised its holdings in shares of Gilead Sciences by 0.6% in the 3rd quarter. Greenleaf Trust now owns 24,345 shares of the biopharmaceutical company’s stock valued at $3,629,000 after buying an additional 157 shares during the period. Finally, Leonard Rickey Investment Advisors P.L.L.C. purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at $220,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares in the company, valued at $16,273,727.76. The trade was a 19.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the chief financial officer owned 161,096 shares in the company, valued at $25,166,417.12. The trade was a 1.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 96,000 shares of company stock valued at $13,923,210. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $170.68 on Monday. The stock has a market cap of $211.63 billion, a P/E ratio of -54.01 and a beta of 0.35. The business’s fifty day simple moving average is $150.87 and its 200-day simple moving average is $139.79. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $175.65. The company has a current ratio of 1.32, a quick ratio of 0.95 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The firm had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the previous year, the firm posted $2.47 EPS. Gilead Sciences’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, equities analysts predict that Gilead Sciences, Inc. will post -1.03 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GILD. Royal Bank Of Canada raised their target price on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a report on Friday. UBS Group reaffirmed a “buy” rating and issued a $195.00 target price (up from $175.00) on shares of Gilead Sciences in a research report on Friday. Cantor Fitzgerald boosted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday. BMO Capital Markets reissued an “outperform” rating and set a $184.00 price target on shares of Gilead Sciences in a research report on Friday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $169.19.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Several analysts raised their price targets for Gilead, setting targets of $175, $181, $183, $188, $190, and $200, while another raised its target to $131. The cluster of increases suggests improving confidence in Gilead’s earnings outlook and valuation. Gilead price target raised to $190 Gilead price target raised to $175 Gilead price target raised to $131 Gilead price target raised to $188 Gilead price target raised to $200 Gilead price target raised to $183 Gilead price target raised to $181
• Positive Sentiment: Morgan Stanley reiterated a Buy view on Gilead, adding to the positive analyst sentiment and supporting the case that the company’s HIV franchise and broader pipeline can sustain growth. Gilead receives a Buy from Morgan Stanley
• Positive Sentiment: Recent coverage points to strong HIV drug sales as a key reason GILD reached new highs. A separate investment article also highlighted Gilead as an attractive dividend-paying biotech, reinforcing its appeal to income-focused investors. Why GILD surged to 52-week highs Dividend-paying biotech stock article
• Neutral Sentiment: Gilead plans to present at upcoming fourth-quarter investor conferences, potentially giving management an opportunity to provide updates on its pipeline, commercial performance, and guidance. Gilead investor conference presentations
• Neutral Sentiment: A peer comparison and a separate analyst rating update provide additional valuation context, but the available headlines do not specify enough detail to determine a direct effect on GILD. Gilead and rivals comparison Gilead analyst rating update
• Negative Sentiment: Gilead’s third-quarter outlook contains a cautionary element: revenue guidance was raised, but the EPS outlook worsened. That contradiction may limit gains if investors focus on margins, expenses, or earnings quality despite the strength of the HIV business. Gilead third-quarter earnings analysis

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.